Market Overview

Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs


Pfizer today announced it will increase its commitment to U.S.
manufacturing with a $465 million investment to build one of the most
technically advanced sterile injectable pharmaceutical production
facilities in the world in Portage, Michigan. This U.S. investment will
strengthen Pfizer's capability to produce and supply critical,
life-saving injectable medicines for patients around the world.

Known as Modular Aseptic Processing (MAP), the new, multi-story,
400,000-square-foot production facility will also support the area
economy by creating an estimated 450 new jobs over the next
several years. This expands Pfizer's presence in Portage, located in
Kalamazoo County, where the company now employs more than 2,200 people
at one of its largest plants.

"This investment is part of our overall plan announced in January to
invest approximately $5 billion in U.S.-based capital projects as a
result of the enactment of the Tax Cuts and Jobs Act. During the next
six years, we expect to invest approximately $1.1 billion in Kalamazoo
County – which is in addition to the $1 billion we have invested in the
site over the past decade," said Ian Read, Chairman and Chief Executive
Officer. "Every day, we strive to enhance our ability to bring medicines
to the patients who need them, and the new facility we are building in
Michigan will help us continue to deliver therapies that significantly
improve people's lives."

"This investment will strengthen Pfizer's leadership in sterile
manufacturing technology and help meet growing patient demand," said
Kirsten Lund-Jurgensen, Ph.D., Executive Vice President and
President, Pfizer Global Supply. "It also will create hundreds of highly
skilled jobs, fortifying Michigan's high-tech manufacturing environment."

Ron Perry, Site Leader for the Portage plant, said the new sterile
injectable facility will strengthen the site's role in Pfizer's global
network. "Sterile drug product manufacturing is incredibly complex. This
contemporary facility will combine cutting-edge technology and a highly
talented workforce to assure we remain a trusted and reliable supplier
of these therapies to patients."

MAP will incorporate the most technically advanced aseptic manufacturing
equipment, systems and design, including multiple, self-contained
modular manufacturing lines. This allows the manufacturing line in each
module to be entirely separate from all other manufacturing lines.
Groundbreaking is planned for spring 2019, with construction expected to
be completed in 2021. After the facility is validated by regulatory
agencies, production should begin in 2024.

To glimpse the technology and talent involved, follow these links for
video interviews with Pfizer Global Supply colleagues based in Portage: Blanca
, senior process engineer; Amber
, customer project manager; and Travis
, machine repairman.

Pfizer's Portage site is a primary global supplier of sterile
injectable, liquids and semi-solid medicines, and active pharmaceutical
ingredients, producing more than 150 products. Its biggest product is
Solu-Medrol, a widely used injectable anti-inflammatory medicine. The
plant has been in operation since 1948, and Pfizer has had a presence in
the community through the legacy Upjohn Company since 1886. Pfizer's
operations in Kalamazoo County generate an estimated annual economic
impact in west Michigan of $2.2 billion.

"Pfizer's investment is a major boost to the state's pharmaceutical
industry and further diversifies Michigan's business environment,"
Michigan Gov. Rick Snyder said. "I appreciate Pfizer's long-term
commitment and the economic benefits this will bring to the region and
the people who live there."

About Pfizer Manufacturing:

Pfizer is a 168-year-old American company founded in Brooklyn, NY.
Pfizer is a proud U.S. based manufacturing and supply company with more
than 11,000 U.S. based employees. With 15 plants, the United States
hosts more Pfizer manufacturing sites than any other country in the

Pfizer Inc: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world's
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world's
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at
In addition, to learn more, please visit us on
and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube
and like us on Facebook at

PFIZER DISCLOSURE NOTICE: The information contained in this release
is as of July 24, 2018. Pfizer assumes no obligation to update
forward-looking statements contained in this release as the result of
new information or future events or developments.

This release contains forward-looking information about Pfizer's plan
to build a new sterile injectable facility in Portage, Michigan,
including its potential benefits and the anticipated timing of
completion and production, that involves substantial risks and
uncertainties that could cause actual results to differ materially from
those expressed or implied by such statements. Risks and uncertainties
include, among other things, risks related to the ability to realize the
anticipated benefits of the new facility and the ability to complete
construction and begin production in the anticipated timeframe or at
all; other business effects, including the effects of industry, market,
economic, political or regulatory conditions; and competitive

A further description of risks and uncertainties can be found in
Pfizer's Annual Report on Form 10-K for the fiscal year ended December
31, 2017 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned "Risk Factors" and "Forward-Looking
Information and Factors That May Affect Future Results", as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at and

View Comments and Join the Discussion!